Tumor-suppressive functions of protein lysine methyltransferases

참고문헌 (221)

1. Feinberg, A. P., "The history of cancer epigenetics", Nat. Rev. Cancer, 4, pp.143~153 (2004)
2. Ibrahim, R. K., "Plant O-methyltransferases : molecular analysis, common signature and classification", Plant Mol. Biol, 36, pp.1~10 (1998)
3. Weisiger, R. A., "Thiol S-methyltransferase", Methods Enzymol, 77, pp.257~262 (1981)
4. Yoo Jung Park, "Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis", Experimental and Molecular Medicine, 54, pp.2107~2117 (2022), 생화학분자생물학회[DOI]
5. Kouzarides, T., "Histone methylation in transcriptional control", Curr. Opin. Genet. Dev, 12, pp.198~209 (2002)
6. 현광범, "Writing, erasing and reading histone lysine methylations", Experimental and Molecular Medicine, 49, pp.1~22 (2017), 생화학분자생물학회
7. Kim Junil, "Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation", Experimental and Molecular Medicine, 54, pp.1~12 (2022), 생화학분자생물학회[DOI]
8. Li Guodong, "Homocysteine-targeting compounds as a new treatment strategy for diabetic wounds via inhibition of the histone methyltransferase SET7", 9, 2022, pp.54, 1~11[DOI]
9. Haiyan Peng, "Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16− NK-cell differentiation", Experimental and Molecular Medicine, 54, pp.1~16 (2022), 생화학분자생물학회
10. Santos-Rosa, H., "Active genes are tri-methylated at K4 of histone H3", Nature, 419, pp.407~411 (2002)
11. Ng, H. H., "Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells : a potential mechanism for position-effect variegation", Proc. Natl Acad. Sci. USA, 100, pp.1820~1825 (2003)
12. Schotta, G., "A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin", Genes Dev, 18, pp.1251~1262 (2004)
13. Wiles, E. T., "H3K27 methylation : a promiscuous repressive chromatin mark", Curr. Opin. Genet. Dev, 43, pp.31~37 (2017)
14. Jacob, Y., "ATXR5 and ATXR6 are H3K27 monomethyltransferases required for chromatin structure and gene silencing", Nat. Struct. Mol. Biol, 16, pp.763~768 (2009)
15. Ferrari, K. J., "Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity", Mol. Cell, 53, pp.49~62 (2014)
16. Shoaib, M., "Histone H4 lysine 20 mono-methylation directly facilitates chromatin openness and promotes transcription of housekeeping genes", Nat. Commun, 12, pp.4800~ (2021)
17. Carlson, S. M., "Proteome-wide enrichment of proteins modified by lysine methylation", Nat. Protoc, 9, pp.37~50 (2014)
18. Guo, A., "Immunoaffinity enrichment and mass spectrometry analysis of protein methylation", Mol. Cell Proteom, 13, pp.372~387 (2014)
19. Hornbeck, P. V., "PhosphoSitePlus : a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse", Nucleic Acids Res, 40, pp.D261~D270 (2012)
20. Copeland, R. A., "Protein methyltransferase inhibitors as precision cancer therapeutics : a decade of discovery", Philos. Trans. R. Soc. Lond. B Biol. Sci, 373, pp.20170080~ (2018)
21. Hamamoto, R., "Dysregulation of protein methyltransferases in human cancer : an emerging target class for anticancer therapy", Cancer Sci, 107, pp.377~384 (2016)
22. Schubert, H. L., "Many paths to methyltransfer : a chronicle of convergence", Trends Biochem. Sci, 28, pp.329~335 (2003)
23. Dillon, S. C., "The SET-domain protein superfamily : protein lysine methyltransferases", Genome Biol, 6, pp.227~ (2005)
24. Trievel, R. C., "Structure and catalytic mechanism of a SET domain protein methyltransferase", Cell, 111, pp.91~103 (2002)
25. Feng, Q., "Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain", Curr. Biol, 12, pp.1052~1058 (2002)
26. Weirich, S., "Encyclopedia of Cancer", pp.538~550 (2019), Elsevier
27. Liao, Q., "Novel insights into histone lysine methyltransferases in cancer therapy : From epigenetic regulation to selective drugs", J. Pharm. Anal, 13, pp.127~141 (2023)
28. Chen, Y., "Increased expression of SETD7 promotes cell proliferation by regulating cell cycle and indicates poor prognosis in hepatocellular carcinoma", PLOS One, 11, pp.e0154939~ (2016)
29. Duan, B., "Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients", EBioMedicine, 37, pp.134~143 (2018)
30. Gu, Y., "SET7", 9 promotes hepatocellular carcinoma progression through regulation of E2F1, 2018, pp.40, 1863~1874
31. Zhang, Y., "The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer", Oncotarget, 7, pp.9859~ (2016)
32. Oudhoff, M. J., "SETD7 controls intestinal regeneration and tumorigenesis by regulating Wnt", β-catenin and Hippo, Dev. Cell, pp.2016, 37[DOI]
33. Song, H., "Isoform-specific lysine methylation of RORα2 by SETD7 is required for association of the TIP60 coactivator complex in prostate cancer progression", Int. J. Mol. Sci, 21, pp.1622~ (2020)
34. Wang, C., "Histone methyltransferase Setd7 regulates Nrf2 signaling pathway by phenethyl isothiocyanate and ursolic acid in human prostate cancer cells", Mol. Nutr. Food Res, 62, pp.1700840~ (2018)
35. Liu, Q., "Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase", Biochim. Biophys. Act, 1853, pp.881~891 (2015)
36. Guo, S., "EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features", Diagn. Pathol, 11, pp.41~ (2016)
37. Bachmann, I. M., "EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast", J. Clin. Oncol, 24, pp.268~273 (2006)
38. Dong, M., "Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1alpha, refines relapse risk and predicts poor outcome for breast cancer", Oncol. Rep, 32, pp.1101~1107 (2014)
39. Chen, Z., "Expression of EZH2 is associated with poor outcome in colorectal cancer", Oncol. Lett, 15, pp.2953~2961 (2018)
40. Ohuchi, M., "Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer", Oncol. Lett, 16, pp.5275~5281 (2018)
41. Varambally, S., "The polycomb group protein EZH2 is involved in progression of prostate cancer", Nature, 419, pp.624~629 (2002)
42. Kleer, C. G., "EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells", Proc. Natl Acad. Sci. USA, 100, pp.11606~11611 (2003)
43. Cao, Q., "Repression of E-cadherin by the polycomb group protein EZH2 in cancer", Oncogene, 27, pp.7274~7284 (2008)
44. Purkait, S., "EZH2 expression in gliomas : correlation with CDKN2A gene deletion", p16 loss and MIB-1 proliferation index, 2015, pp.35, 421~431
45. Velichutina, I., "EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis", Blood, 116, pp.5247~5255 (2010)
46. Chen, Q., "EZH2-mediated repression of GSK-3beta and TP53 promotes Wnt", beta-catenin signaling-dependent cell expansion in cervical carcinoma, 2016, pp.7, 36115~36129
47. Liao, Y., "Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress", Proc. Natl Acad. Sci. USA, 119, pp.e2105898119~ (2022)
48. Rastgoo, N., "Dysregulation of EZH2", miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS, 2018, pp.32, 2471~2482
49. Comet, I., "Maintaining cell identity : PRC2-mediated regulation of transcription and cancer", Nat. Rev. Cancer, 16, pp.803~810 (2016)
50. de Vries, N. A., "Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression", Cell Rep, 10, pp.383~397 (2015)
51. Dhar, S., "A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis", Acta Neuropathol. Commun, 10, pp.47~ (2022)
52. Huang, J., "G9a and Glp methylate lysine 373 in the tumor suppressor p53", J. Biol. Chem, 285, pp.9636~9641 (2010)
53. Zhong, X., "Overexpression of G 9a and MCM 7 in oesophageal squamous cell carcinoma is associated with poor prognosis", Histopathology, 66, pp.192~200 (2015)
54. Chen, M. -W., "H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM", Cancer Res, 70, pp.7830~7840 (2010)
55. Hua, K. -T., "The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis", Mol. Cancer, 13, pp.1~13 (2014)
56. Lee, S., "Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells", Oncogene, 28, pp.184~194 (2009)
57. Komatsu, S., "Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma", Carcinogenesis, 30, pp.1139~1146 (2009)
58. Cho, H. -S., "RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation", Neoplasia, 14, pp.476~478 (2012)
59. Huang, J., "Repression of p53 activity by Smyd2-mediated methylation", Nature, 444, pp.629~632 (2006)
60. Saddic, L. A., "Methylation of the retinoblastoma tumor suppressor by SMYD2", J. Biol. Chem, 285, pp.37733~37740 (2010)
61. Viotti, M., "SUV420H2 is an epigenetic regulator of epithelial", mesenchymal states in pancreatic cancer, 2018, pp.217, 763~777
62. Li, Y., "The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate", J. Biol. Chem, 284, pp.34283~34295 (2009)
63. Qiao, Q., "The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation", J. Biol. Chem, 286, pp.8361~8368 (2011)
64. Martinez-Garcia, E., "The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14)multiple myeloma cells", Blood, 117, pp.211~220 (2011)
65. Morishita, M., "In vitro histone lysine methylation by NSD1, NSD2", MMSET, WHSC1L, pp.BMC Struct. Biol, 2014[DOI]
66. Martinelli, G., "SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis", Leukemia, 32, pp.139~148 (2018)
67. Xiang, W., "miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma", Oncotarget, 6, pp.4066~4079 (2015)
68. Hacker, K. E., "Structure", function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone H3 lys-36 trimethylation, 2016, pp.291, 21283~21295
69. Li, J., "SETD2 : an epigenetic modifier with tumor suppressor functionality", Oncotarget, 7, pp.50719~50734 (2016)
70. Chiang, Y. C., "SETD2 haploinsufficiency for microtubule methylation is an early driver of genomic instability in renal cell carcinoma", Cancer Res, 78, pp.3135~3146 (2018)
71. Duns, G., "Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma", Cancer Res, 70, pp.4287~4291 (2010)
72. Kanu, N., "SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair", Oncogene, 34, pp.5699~5708 (2015)
73. Carvalho, S., "SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint", Elife, 3, pp.e02482~ (2014)
74. Li, L., "Integrated genomic and proteomic analyses reveal novel mechanisms of the methyltransferase SETD2 in renal cell carcinoma development", Mol. Cell Proteom, 18, pp.437~447 (2019)
75. Liu, J., "Loss of SETD2 induces a metabolic switch in renal cell carcinoma cell lines toward enhanced oxidative phosphorylation", J. Proteome Res, 18, pp.331~340 (2019)
76. Li, J., "Functional studies on primary tubular epithelial cells indicate a tumor suppressor role of SETD2 in clear cell renal cell carcinoma", Neoplasia, 18, pp.339~346 (2016)
77. Zhang, Y. L., "Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation", Cell Res, 28, pp.476~490 (2018)
78. Bu, J., "SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia", Leukemia, 32, pp.890~899 (2018)
79. Chen, B. Y., "SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS", Blood, 135, pp.2271~2285 (2020)
80. Parker, H., "Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia", Leukemia, 30, pp.2179~2186 (2016)
81. Mar, B. G., "Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia", Nat. Commun, 5, pp.3469~ (2014)
82. Mar, B. G., "SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia", Blood, 130, pp.2631~2641 (2017)
83. Dong, Y., "SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints", Leukemia, 33, pp.2585~2598 (2019)
84. Sheng, Y., "Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells", Cell Prolif, 52, pp.e12611~ (2019)
85. Niu, N., "Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis", Gut, 69, pp.715~726 (2020)
86. Niu, N., "Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis", Adv. Sci, 10, pp.e2202937~ (2023)
87. Walter, D. M., "Systematic in vivo inactivation of chromatin-regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma", Cancer Res, 77, pp.1719~1729 (2017)
88. Xie, Y., "SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis", JCI Insight, 8, pp.e154120~ (2023)
89. Kim, I. K., "Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer", Oncogene, 38, pp.180~193 (2019)
90. Walter, D. M., "Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling", Commun. Biol, 6, pp.255~ (2023)
91. Chen, Z., "SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion", Biochem. Biophys. Res. Commun, 498, pp.579~585 (2018)
92. Huang, K. K., "SETD2 histone modifier loss in aggressive GI stromal tumours", Gut, 65, pp.1960~1972 (2016)
93. Yuan, H., "Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis", J. Clin. Invest, 127, pp.3375~3391 (2017)
94. Bushara, O., "Clinical and histopathologic characterization of SETD2-mutated colorectal cancer", Hum. Pathol, 131, pp.9~16 (2023)
95. Ganaie, I. A., "Reduced expression of SETD2 and SNX9 proteins in chemically induced mammary tumorigenesis in Wistar rats : a prognostic histological and proteomic study", Protoplasma, 254, pp.1451~1466 (2017)
96. Jiang, C., "Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt", β-catenin signaling, 2018, pp.502, 382~388
97. Bhattacharya, S., "Elevated levels of the methyltransferase SETD2 causes transcription and alternative splicing changes resulting in oncogenic phenotypes", Front. Cell Dev. Biol, 10, pp.945668~ (2022)
98. Kurash, J. K., "Methylation of p53 by Set7", 9 mediates p53 acetylation and activity in vivo, 2008, pp.29, 392~400
99. Donehower, L. A., "Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours", Nature, 356, pp.215~221 (1992)
100. Shen, C., "SET7", 9 regulates cancer cell proliferation by influencing beta-catenin stability, 2015, pp.29, 4313~4323
101. Akiyama, Y., "Reduced expression of SET7", 9, a histone mono-methyltransferase, is associated with gastric cancer progression, 2016, pp.7, 3966~3983
102. Hu, H. Y., "Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells", Acta Pharmacol. Sin, 34, pp.157~166 (2013)
103. Montenegro, M. F., "Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis", Oncogene, 35, pp.6143~6152 (2016)
104. Song, Y., "SET7", 9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer, 2016, pp.37, 9311~9322
105. Cao, L., "Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2", STAT3 pathway, 2020, pp.45, 1616~1626
106. Xie, H., "METTL3", YTHDF2 m6A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer, 2020, pp.24, 4092~4104
107. Wang, Y., "Ezh2 Acts as a tumor suppressor in Kras-driven lung adenocarcinoma", Int. J. Biol. Sci, 13, pp.652~659 (2017)
108. Li, Z., "The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2", FEBS Lett, 588, pp.3000~3007 (2014)
109. Ernst, T., "Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders", Nat. Genet, 42, pp.722~726 (2010)
110. Bejar, R., "Clinical effect of point mutations in myelodysplastic syndromes", N. Engl. J. Med, 364, pp.2496~2506 (2011)
111. Guglielmelli, P., "EZH2 mutational status predicts poor survival in myelofibrosis", Blood, 118, pp.5227~5234 (2011)
112. Muto, T., "Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders", J. Exp. Med, 210, pp.2627~2639 (2013)
113. Sashida, G., "Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation", Nat. Commun, 5, pp.4177~ (2014)
114. Nangalia, J., "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N. Engl. J. Med, 369, pp.2391~2405 (2013)
115. Mullally, A., "Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells", Cancer Cell, 17, pp.584~596 (2010)
116. Sashida, G., "The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition", J. Exp. Med, 213, pp.1459~1477 (2016)
117. Simon, C., "A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia", Genes Dev, 26, pp.651~656 (2012)
118. Ntziachristos, P., "Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia", Nat. Med, 18, pp.298~301 (2012)
119. Gollner, S., "Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia", Nat. Med, 23, pp.69~78 (2017)
120. Krill, L., "Overexpression of enhance of Zeste homolog 2(EZH2)in endometrial carcinoma : An NRG oncology", Gynecologic oncology group study, 2020, pp.156, 423~429
121. Qiu, B. Q., "Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101", EZH2 axis as a ceRNA, 2020, pp.12, 1843~1856
122. Gan, L., "The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter", J. Hematol. Oncol, 11, pp.9~ (2018)
123. Pellecchia, S., "The long non-coding RNA prader Willi", Angelman region RNA5(PAR5)is downregulated in anaplastic thyroid carcinomas where it acts as a tumor suppressor by reducing EZH2 activity, 2020, pp.12, 235~
124. Fan, D. C., "MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma", Auris Nasus Larynx, 47, pp.632~642 (2020)
125. Yu, H., "Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair", Proc. Natl Acad. Sci. USA, 111, pp.285~290 (2014)
126. Sun, C., "EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis", J. Cancer, 9, pp.3787~3796 (2018)
127. Zauderer, M. G., "EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma : a multicentre, open-label, phase 2 study", Lancet Oncol, 23, pp.758~767 (2022)
128. LaFave, L. M., "Loss of BAP1 function leads to EZH2-dependent transformation", Nat. Med, 21, pp.1344~1349 (2015)
129. Ciarapica, R., "Deregulated expression of miR-26a and Ezh2 in Rhabdomyosarcoma", Cell Cycle, 8, pp.172~175 (2009)
130. Richter, G. H. S., "EZH2 is a mediator of EWS", FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation, 2009, pp.106, 5324~5329
131. McCabe, M. T., "Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27(H3K27)", Proc. Natl Acad. Sci. USA, 109, pp.2989~2994 (2012)
132. Yap, D. B., "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation", Blood, 117, pp.2451~2459 (2011)
133. Morin, R. D., "Somatic mutations altering EZH2(Tyr641)in follicular and diffuse large B-cell lymphomas of germinal-center origin", Nat. Genet, 42, pp.181~185 (2010)
134. Ogawa, S., "Genetic basis of myelodysplastic syndromes", Proc. Jpn. Acad. Ser. B Phys. Biol. Sci, 96, pp.107~121 (2020)
135. Simon, J. A., "Roles of the EZH2 histone methyltransferase in cancer epigenetics", Mutat. Res, 647, pp.21~29 (2008)
136. Antonysamy, S., "Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain", PLoS One, 8, pp.e84147~ (2013)
137. Chase, A., "Mutational mechanisms of EZH2 inactivation in myeloid neoplasms", Leukemia, 34, pp.3206~3214 (2020)
138. Zhou, B., "PRDM16 sppresses MLL1r leukemia via itrinsic hstone mthyltransferase ativity", Mol. Cell, 62, pp.222~236 (2016)
139. Alam, H., "KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer", Cancer Cell, 37, pp.599~617 (2020)
140. Ortega-Molina, A., "The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development", Nat. Med, 21, pp.1199~1208 (2015)
141. Zhang, J., "Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis", Nat. Med, 21, pp.1190~1198 (2015)
142. Dhar, S. S., "MLL4 is required to maintain broad H3K4me3 peaks and super-enhancers at tumor suppressor genes", Mol. Cell, 70, pp.825~841 (2018)
143. Du, D., "Smad3-mediated recruitment of the methyltransferase SETDB1", ESET controls Snail1 expression and epithelial-mesenchymal transition, 2018, pp.19, 135~155
144. Abaev-Schneiderman, E., "SETD3 is a positive regulator of DNA-damage-induced apoptosis", Cell Death Dis, 10, pp.74~ (2019)
145. Zhu, B., "The protective role of DOT1L in UV-induced melanomagenesis", Nat. Commun, 9, pp.259~ (2018)
146. Berdasco, M., "Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma", Proc. Natl Acad. Sci. USA, 106, pp.21830~21835 (2009)
147. Cancer Genome Atlas Research, N., "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia", N. Engl. J. Med, 368, pp.2059~2074 (2013)
148. Garg, M., "Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse", Blood, 126, pp.2491~2501 (2015)
149. Kayser, S., "Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients", Eur. J. Haematol, 99, pp.544~552 (2017)
150. Chen, C., "MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia", Cancer Cell, 25, pp.652~665 (2014)
151. Yeh, C. -H., "Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia", Mol. Cancer, 15, pp.15~ (2016)
152. Watanabe, Y., "Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer", PLoS One, 6, pp.e23320~ (2011)
153. Rampias, T., "The lysine-specific methyltransferase KMT 2C", MLL 3 regulates DNA repair components in cancer, 2019, pp.20, e46821~
154. Lee, J., "A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4", Proc. Natl Acad. Sci. USA, 106, pp.8513~8518 (2009)
155. Buyse, I. M., "The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein", Proc. Natl Acad. Sci. USA, 92, pp.4467~4471 (1995)
156. Steele-Perkins, G., "Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily", Genes Dev, 15, pp.2250~2262 (2001)
157. Piao, G. H., "Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma", Histol. Histopathol, 23, pp.1171~1175 (2008)
158. Liu, Z. Y., "Retinoblastoma protein-interacting zinc-finger gene 1(RIZ1)dysregulation in human malignant meningiomas", Oncogene, 32, pp.1216~1222 (2013)
159. He, L., "RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and", or apoptosis, 1998, pp.58, 4238~4244
160. Cai, Z., "RIZ1 negatively regulates ubiquitin-conjugating enzyme E2C", UbcH10 via targeting c-Myc in meningioma, 2017, pp.9, 2645~2655
161. Zhang, C., "RIZ1 : a potential tumor suppressor in glioma", BMC Cancer, 15, pp.990~ (2015)
162. Wei, D., "The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc", J. Gene, 737, pp.144456~ (2020)
163. van Ree, J. H., "Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation", J. Cell Biol, 188, pp.83~100 (2010)
164. Tokumaru, Y., "Biallelic inactivation of the RIZ1 gene in human gastric cancer", Oncogene, 22, pp.6954~6958 (2003)
165. Du, Y., "Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone", protein methyltransferase superfamily, 2001, pp.61, 8094~8099
166. Jiang, G., "Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1", Int. J. Cancer, 83, pp.541~546 (1999)
167. Jiang, G. L., "Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers", Cancer Res, 61, pp.1796~1798 (2001)
168. Piao, Z., "Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability", Cancer Res, 60, pp.4701~4704 (2000)
169. Yang, T., "RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer", Biochem. Biophys. Res. Commun, 489, pp.96~102 (2017)
170. Huang, S., "The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers", Front. Biosci, 4, pp.D528~D532 (1999)
171. Di Zazzo, E., "Critical function of PRDM2 in the neoplastic growth of testicular germ cell tumors", Biology, 5, pp.54~ (2016)
172. Pastural, E., "RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines", Oncogene, 26, pp.1586~1594 (2007)
173. Bond, C. E., "Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups", BMC Cancer, 15, pp.20~ (2015)
174. Watanabe, Y., "PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer", Clin. Cancer Res, 13, pp.4786~4794 (2007)
175. Deng, Q., "PRDM5 is silenced in human cancers and has growth suppressive activities", Oncogene, 23, pp.4903~4910 (2004)
176. Galli, G. G., "Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression", Oncogene, 33, pp.3342~3350 (2014)
177. Shu, X. -s, "The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT", β-catenin signaling and is frequently silenced in multiple tumors, 2011, pp.6, e27346~
178. Hu, L., "Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development", Cancer Res, 69, pp.4067~4072 (2009)
179. Song, J., "Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis", Oncol. Lett, 17, pp.3851~3861 (2019)
180. Han, S., "miR-1307-3p stimulates breast cancer development and progression by targeting SMYD4", J. Cancer, 10, pp.441~448 (2019)
181. Yan, L., "Genetic alteration of histone lysine methyltransferases and their significance in renal cell carcinoma", PeerJ, 7, pp.e6396~ (2019)
182. Noroxe, D. S., "Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility-a prospective, translational study", Mol. Oncol, 14, pp.2727~2743 (2020)
183. Shinchi, Y., "SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3", Exp. Cell Res, 334, pp.90~99 (2015)
184. Wu, Y., "miR-29a contributes to breast cancer cells epithelial-mesenchymal transition, migration, and invasion via down-regulating histone H4K20 trimethylation through directly targeting SUV420H2", Cell Death Dis, 10, pp.176~ (2019)
185. Pogribny, I. P., "Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats", Carcinogenesis, 27, pp.1180~1186 (2006)
186. Van Den Broeck, A., "Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer", Clin. Cancer Res, 14, pp.7237~7245 (2008)
187. Piao, L., "Loss of histone H4 lysine 20 trimethylation in osteosarcoma is associated with aberrant expression ofhistone methyltransferase SUV420H2", Oncol. Lett, 20, pp.26~ (2020)
188. Hong, Y. H., "The EEF1AKMT3", MAP2K7, Cancer Lett, pp.2022, 544[DOI]
189. Knutson, S. K., "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma", Mol. Cancer Ther, 13, pp.842~854 (2014)
190. Serresi, M., "Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities", J. Exp. Med, 215, pp.3115~3135 (2018)
191. Al-Ghabkari, A., "Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro", Cancer Biol. Ther, 22, pp.333~344 (2021)
192. Wang, Y., "The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type", J. Pathol, 242, pp.371~383 (2017)
193. Sweis, R. F., "Discovery and development of potent and selective inhibitors of histone methyltransferase g9a", ACS Med. Chem. Lett, 5, pp.205~209 (2014)
194. Pappano, W. N., "The histone methyltransferase inhibitor A-366 uncovers a role for G9a", GLP in the epigenetics of leukemia, 2015, pp.10, e0131716~
195. Alexandrova, E., "Histone methyltransferase DOT1L as a promising epigenetic target for treatment of solid tumors", Front. Genet, 13, pp.864612~ (2022)
196. Kim, W., "Deficiency of H3K79 histone methyltransferase Dot1-like protein(DOT1L)inhibits cell proliferation", J. Biol. Chem, 287, pp.5588~5599 (2012)
197. Daigle, S. R., "Potent inhibition of DOT1L as treatment of MLL-fusion leukemia", Blood, 122, pp.1017~1025 (2013)
198. Gelato, K. A., "Targeting epigenetic regulators for cancer therapy : modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs", Expert Opin. Ther. Targets, 20, pp.783~799 (2016)
199. Bhattacharya, S., "Regulation of SETD2 stability is important for the fidelity of H3K36me3 deposition", Epigenetics Chromatin, 13, pp.40~ (2020)
200. Gyorffy, B., "An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients", Breast Cancer Res. Treat, 123, pp.725~731 (2010)
201. Gyorffy, B., "Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients", Endocr. Relat. Cancer, 19, pp.197~208 (2012)
202. Gyorffy, B., "Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer", PLoS One, 8, pp.e82241~ (2013)
203. Szasz, A. M., "Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1, 065 patients", Oncotarget, 7, pp.49322~49333 (2016)
204. Knutson, S. K., "Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2", Proc. Natl Acad. Sci. USA, 110, pp.7922~7927 (2013)
205. Qi, W., "Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation", Proc. Natl Acad. Sci. USA, 109, pp.21360~21365 (2012)
206. McCabe, M. T., "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations", Nature, 492, pp.108~112 (2012)
207. Bradley, W. D., "EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation", Chem. Biol, 21, pp.1463~1475 (2014)
208. Knutson, S. K., "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells", Nat. Chem. Biol, 8, pp.890~896 (2012)
209. Campbell, J. E., "EPZ011989, A potent, orally-available EZH2 inhibitor with robust in vivo activity", ACS Med. Chem. Lett, 6, pp.491~495 (2015)
210. Song, X., "Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation", Biomed. Pharmacother, 81, pp.288~294 (2016)
211. Beguelin, W., "EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation", Cancer Cell, 23, pp.677~692 (2013)
212. Xie, H., "Chronic myelogenous leukemia-initiating cells require polycomb group protein EZH2", Cancer Discov, 6, pp.1237~1247 (2016)
213. Verma, S. K., "Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2", ACS Med. Chem. Lett, 3, pp.1091~1096 (2012)
214. Kung, P. P., "Correction to design and synthesis of pyridone-containing 3, 4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of Zeste Homolog 2(EZH2)inhibitors", J. Med. Chem, 59, pp.11196~ (2016)
215. Garapaty-Rao, S., "Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth", Chem. Biol, 20, pp.1329~1339 (2013)
216. Vaswani, R. G., "Identification of(R)-N-((4-methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2, 2, 2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide(CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-Cell lymphomas", J. Med. Chem, 59, pp.9928~9941 (2016)
217. Lu, B., "Discovery of EBI-2511 : A highly potent and orally active EZH2 inhibitor for the treatment of non-Hodgkin’s lymphoma", ACS Med. Chem. Lett, 9, pp.98~102 (2018)
218. Konze, K. D., "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1", ACS Chem. Biol, 8, pp.1324~1334 (2013)
219. Yamagishi, M., "Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas", Cell Rep, 29, pp.2321~2337 (2019)
220. Honma, D., "Novel orally bioavailable EZH1", 2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor, 2017, pp.108, 2069~2078
221. Kung, P. P., "Optimization of orally bioavailable enhancer of Zeste Homolog 2(EZH2)inhibitors using ligand and property-based design strategies : Identification of development candidate(R)-5, 8-dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl)methyl)-3, 4-dihydroisoquinolin-1(2H)-one(PF-06821497)", J. Med. Chem, 61, pp.650~665 (2018)

관련 논문AI추천